On September 30, Roche stated that the total annual sales of the three early obesity and diabetes candidate drugs under the previously acquired Carmot Therapeutics company may exceed 3 billion swiss francs (equivalent to 3.6 billion US dollars). This revenue forecast applies to the weekly injectable CT-388 (similar to Eli Lilly's Zepbound), the daily oral CT-996, and the CT-868 for treating type 1 diabetes. Roche stated that in its research pipeline, at least seven drugs have peak sales potential exceeding 3 billion francs.
罗氏目标肥胖症药物年销售额超过36亿美元
Roche's annual sales of obesity drugs exceeded $3.6 billion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated